The main objective of this paper is to review the current literature regarding the efficacy and safety of current and emerging IL-13 monoclonal antibodies, including tralokinumab, lebrikizumab, cendakimab, and eblasakimab, for the treatment of moderate-to-severe AD. This evidence concerns the gene IL13 and Alzheimer disease.